Primmune Therapeutics to Present PRTX007 Phase 1 Pharmacology and Phase 2 INFLECTION-003 Study Design at the SITC 41st Annual Meeting
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Primmune Therapeutics, a clinical-stage biotech company harnessing the power of the innate and adaptive immune systems, today announced that two abstracts on polvitolimod HCl (also known as PRTX007), a novel orally administered, systemically acting toll-like receptor 7 (TLR7) agonist, will be presented at the Society for Immunotherapy of […]
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary and secondary endpoints: pathologic Complete Response (pCR; 33% vs. 8%), radiographic Objective Response Rate (ORR; 60% vs. 15%) and Major Pathologic Response (MPR; 60% vs. 23%) Enhanced responses were associated with increased eligibility for bladder-sparing treatment approaches in cisplatin-ineligible or […]
Spica Therapeutics Appoints Jeff Abbey as Chief Executive Officer
New CEO brings over two decades of international life sciences leadership and a proven track record of biotech company building, corporate development, and successful capital formation Appointment aligns with Spica’s strategy to deploy its Macrophage Fingerprinting Platform across high-value chronic disease indications Brussels, Belgium – October 6, 2026 – Spica Therapeutics (“Spica”), a biotechnology company […]
Primmune Therapeutics Announces Enrollment Milestone in Phase 2 INFLECTION–003 Study of Polvitolimod HCl in Neoadjuvant Melanoma
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — Primmune Therapeutics, a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second patient in its Phase 2 INFLECTION-003 clinical study triggering the release of the second tranche of financing. The financing advances the development of Polvitolimod HCl […]
Bioqube welcomes Bonnie van Wilgenburg as Venture Partner
Brussels, Belgium – September 2026 – Bioqube Ventures today announces that Bonnie van Wilgenburg, Ph.D., has joined as Venture Partner. Bonnie will initially lead the development of a new portfolio company currently operating in stealth mode. In parallel, she will support the investment team in sourcing and evaluating new opportunities across Europe and the US, drawing on […]
Actithera significantly strengthens leadership team and Board as Company advances towards clinical development
Steven Kelly appointed Chief Executive Officer to lead Actithera through clinical development and continued pipeline expansion Briggs Morrison appointed Chair of the Board, bringing extensive biotech leadership and oncology drug development expertise John Crowley appointed Independent Director, adding proven strategic, financial and capital markets leadership Oslo, Norway and Cambridge, Massachusetts — 10 September 2026 — […]
CatalYm Appoints Peter Garcia as Chief Financial Officer
Munich, Germany and San Francisco, USA, June 09, 2026 – CatalYm today announced the appointment of Peter Garcia as Chief Financial Officer (CFO). Mr. Garcia brings more than three decades of biotechnology and oncology financial leadership experience, with a proven track record of leading transformative financings, strategic transactions, and scaling finance organizations to support global […]
CatalYm Appoints Christian S. Schade as Chairman of the Board of Directors
Munich, Germany and San Francisco, USA, April 29, 2026 – CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, […]
CatalYm Advances Visugromab into Phase 2/3 Development for Cancer Cachexia with First Patient Dosed
Trial will evaluate visugromab’s potential to reverse cancer-associated weight loss and muscle wasting by targeting GDF-15 in patients with advanced solid tumors Fourth Phase 2b study of visugromab broadens CatalYm’s late-stage development program into severe cancer-associated condition impacting treatment outcomes Munich, Germany and San Francisco, USA, April 23, 2026 – CatalYm today announced that the first patient has […]
SynOx Therapeutics Announces Positive Topline Results from the Phase 3 TANGENT Study, Supporting Emactuzumab as a Differentiated, Next-generation Treatment for Patients with Tenosynovial Giant Cell Tumor (TGCT)
TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in PROMIS-PF and other patient -relevant functional measures Rapid onset and significant functional improvement observed Short-course regimen demonstrated sustained and durable clinical […]